MetaVia Inc. (MTVA) stock
MTVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.25+0.04 (+3.73%)
Close on Nov 17, 2026Market cap $8.24MP/E –Yield –
MetaVia operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
MetaVia's operating income for the twelve months ending Jun 30, 2026 was -$14.93M. For fiscal 2025 it was -$13.71M. The highest annual figure on record is -$266.00K in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.71M | – |
| FY2024 | Dec 31, 2024 | -$28.81M | – |
| FY2023 | Dec 31, 2023 | -$15.89M | – |
| FY2022 | Dec 31, 2022 | -$19.63M | – |
| FY2021 | Dec 31, 2021 | -$15.30M | – |
| FY2020 | Dec 31, 2020 | -$29.72M | – |
| FY2019 | Dec 31, 2019 | -$20.18M | – |
| FY2018 | Dec 31, 2018 | -$15.49M | – |
| FY2017 | Dec 31, 2017 | -$33.12M | – |
| FY2016 | Dec 31, 2016 | -$14.70M | – |
| FY2015 | Dec 31, 2015 | -$8.08M | – |
| FY2014 | Dec 31, 2014 | -$266.00K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.05M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.30M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.59M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.67M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.89M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.43M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.88M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.46M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.93M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.33M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.52M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.39M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.75M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.19M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.65M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.89M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.45M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.30M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.91M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.53M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.06M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.57M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.54M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.52M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.50M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.23M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.40M | – |
See a number that looks wrong?